Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AZD9829 in CD123-positive hematologic malignancies
jRCT2051230181Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of AZD9829 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and hematopoietic malignancies, sponsored by AstraZeneca. Primary endpoints: Frequency of dose limiting toxicities and Safety evaluation of AZD9829 (treatment-related adverse events). Started Jan 2024; status: completed.
02
Drugs
AZD9829
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)hematopoietic malignancies
Beyond the preview
Go deeper on jRCT2051230181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230181.